Cellectar Biosciences enrolled its first patient in its Phase 1b clinical trial evaluating iopofosine I 131 in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG), the company announced today.

According to a release, the open-label study will assess two dosing regimens to identify the optimal iopofosine I 131 Phase 2 recommended dose and schedule in pHGGG patients and evaluate safety and tolerability.

Click here to read the full article.